Summary
Corticosteroids are the most effective therapy for chronic immune and inflammatory diseases in current use. Despite their success over the past 50 years, and especially since the advent of new potent halogenated compounds, worries about the detrimental side-effects of systemic corticosteroids has limited their effectiveness in severe disease. This has resulted in the increasing use of TOPICAL corticosteroids targeted to the site of inflammation rather than systemic administration. Improvements in risk/benefit ratios are likely to occur, as greater understanding of the role of chemical substitutions of the synthetic corticosteroid becomes clear, and more potent tissue selective drugs are developed. Drugs that target distinct aspects of corticosteroid function, switching on or off genes, are also under development and along with non-steroidal agents that target different aspects of the inflammatory response are likely to lead to safer drugs with a much reduced side-effect profile. However, until these become widely available, current systemic and TOPICAL corticosteroids are likely to remain the major treatment for most inflammatory diseases.
Keywords
- Fluticasone Propi
- Allergy Clin Immunol
- Topical Corticosteroid
- Immune Thrombocytopenic Purpura
- Beclomethasone Dipropionate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected readings
Eggert M, Schulz M, Neeck G (2001) Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77: 185–191
Friend DR (1998) Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12: 591–603
Hofer KN (2003) Oral budesonide in the management of Crohn’s disease. Ann Pharmacother 37: 1457–1464
Leung DY, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111: 3–22
Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96: 115–123
Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side-effects of glucocorticoids. Pharmacol Ther 96: 23–43
References
Magiakou MA, Chrousos GP (2002) Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J Endocrinol Invest 25: 181–194
Kino T, Vottero A, Charmandari E, Chrousos GP (2002) Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann NY Acad Sci 970: 101–111
Barnes PJ, Adcock IM (2003) How do corticosteroids work in asthma? Ann Intern Med 139: 359–370
Raju TN (1999) The Nobel chronicles. 1950: Edward Calvin Kendall (1886–1972); Philip Showalter Hench (1896–1965); and Tadeus Reichstein (1897–1996). Lancet 353: 1370
Caramori G, Adcock I (2003) Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 16: 247–277
Johnson M (1996) Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97: 169–176
Brattsand R, Thalen A, Roempke K, Kallstrom L, Gruvstad E (1982) Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 16: 779–786
Adcock IM (2003) Glucocorticoids: new mechanisms and future agents. Curr Allergy Asthma Rep 3: 249–257
Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290
Shim J, Karin M (2002) The control of mRNA stability in response to extracellular stimuli. Mol Cells 14: 323–331
Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G (2001) Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20: 7168–7173
Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P et al (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93: 531–541
Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3: 27–41
Buttgereit F, Scheffold A (2002) Rapid glucocorticoid effects on immune cells. Steroids 67: 529–534
Croxtall JD, Van Hal PT, Choudhury Q, Gilroy DW, Flower RJ (2002) Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 135: 511–519
Leung DY, Bloom JW (2003) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111: 3–22
Eggert M, Schulz M, Neeck G (2001) Molecular mechanisms of glucocorticoid action in rheumatic autoimmune diseases. J Steroid Biochem Mol Biol 77: 185–191
Morand EF (1998) Corticosteroids in the treatment of rheumatologic diseases. Curr Opin Rheumatol 10: 179–183
Adcock IM, Chung KF (2002) Overview: why are corticosteroids ineffective in COPD? Curr Opin Investig Drugs 3: 58–60
Huber MR, Kumar S, Tefferi A (2003) Treatment advances in adult immune thrombocytopenic purpura. Ann Hematol 82: 723–737
Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A (1981) Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 304: 5–9
Wilson JW, Djukanovic R, Howarth PH, Holgate ST (1994) Inhaled beclomethasone dipropionate down-regulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 149: 86–90
Schleimer RP, Bochner BS (1994) The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 94: 1202–1213
Redington AE, Wilson JW, Walls AF, Madden J, Djukanovic R, Holgate ST, Howarth PH (2000) Persistent airway T-lymphocyte activation in chronic corticosteroid-treated symptomatic asthma. Ann Allergy Asthma Immunol 85: 501–507
in’t Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH (1999) Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 160: 93–99
Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH (1999) Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 54: 289–295
Brieva JL, Danta I, Wanner A (2000) Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med 161: 293–296
Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol (Suppl) 65: 16–21
Taylor PC (2003) Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 42: 15–20
Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52: 998–1002
John M, Lim S, Seybold J, Jose P, Robichaud A, O’Connor B, Barnes PJ, Chung KF (1998) Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 157: 256–262
Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston RN, Lee TH (1997) Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1ra) expression in asthmatic bronchial epithelium. Thorax 52: 407–410
McMillan RM (2001) Leukotrienes in respiratory disease. Paediatr Respir Rev 2: 238–244
Thomas E, Leroux JL, Blotman F, Descomps B, Chavis C (1995) Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose. Biochem Pharmacol 49: 243–248
Zaitsu M, Hamasaki Y, Aoki Y, Miyazaki S (2001) A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism. J Allergy Clin Immunol 108: 122–124
Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM (1999) Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45: 382–388
Norman M, Hearing SD (2002) Glucocorticoid resistance — what is known? Curr Opin Pharmacol 2: 723–729
Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57: 226–230
Pickup ME (1979) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 4: 111–128
Swartz SL, Dluhy RG (1978) Corticosteroids: clinical pharmacology and therapeutic use. Drugs 16: 238–255
Colice GL (2000) Comparing inhaled corticosteroids. Respir Care 45: 846–853
Edsbacker S (1999) Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 58(Suppl 4): 7–16
Lundin PD, Edsbacker S, Bergstrand M, Ejderhamn J, Linander H, Hogberg L, Persson T, Escher JC, Lindquist B (2003) Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol Ther 17: 85–92
Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side-effects of glucocorticoids. Pharmacol Ther 96: 23–43
Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96: 115–123
Robertson DB, Maibach HI (1982) Topical corticosteroids. Int J Dermatol 21: 59–67
Schacke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H, Asadullah K (2002) SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 357–371
Charman C, Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21: 193–200
Friend DR (1998) Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 12: 591–603
Sandborn WJ, Feagan BG (2003) Review article: mild to moderate Crohn’s disease — defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 18: 263–277
Cui N, Friend DR, Fedorak RN (1994) A budesonide prodrug accelerates treatment of colitis in rats. Gut 35: 1439–1446
Brattsand R, Linden M (1996) Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10(Suppl 2): 81–90
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG (2002) The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 16: 1509–1517
Hofer KN (2003) Oral budesonide in the management of Crohn’s disease. Ann Pharmacother 37: 1457–1464
Ioannou Y, Isenberg DA (2002) Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 78: 599–606
Pizzuto J, Ambriz R (1984) Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 64: 1179–1183
Barnes PJ (1990) Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 141: S70–S76
van den BM, Kerstjens HA, Meijer RJ, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164: 1127–1132
Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijarvi A et al (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331: 700–705
Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side-effects. Proc Natl Acad Sci USA 101: 227–232
Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R et al (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110: 1713–1718
de Kaski MC, Peters AM, Lavender JP, Hodgson HJ (1991) Fluticasone propionate in Crohn’s disease. Gut 32: 657–661
Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H (2001) Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 14: 141–147
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag
About this chapter
Cite this chapter
Adcock, I.M., Ito, K. (2005). Corticosteroids. In: Nijkamp, F.P., Parnham, M.J. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7408-X_26
Download citation
DOI: https://doi.org/10.1007/3-7643-7408-X_26
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-5804-4
Online ISBN: 978-3-7643-7408-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)